User menu

Prevention of muscle disuse atrophy by MG132 proteasome inhibitor.

Bibliographic reference Jamart, Cécile ; Raymackers, Jean-Marc ; Li An, Gang ; Deldicque, Louise ; Francaux, Marc. Prevention of muscle disuse atrophy by MG132 proteasome inhibitor.. In: Muscle & nerve, Vol. 43, no. 5, p. 708-16 (2011)
Permanent URL http://hdl.handle.net/2078.1/72384
  1. Lecker, J Nutr, 129, 227S (1999)
  2. Yimlamai T., Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway, 10.1152/japplphysiol.00448.2004
  3. Reid M. B., Response of the ubiquitin-proteasome pathway to changes in muscle activity, 10.1152/ajpregu.00545.2004
  4. Taillandier Daniel, Combaret Lydie, Pouch Marie-Noëlle, Samuels Susan E., Béchet Daniel, Attaix Didier, The role of ubiquitin–proteasome-dependent proteolysis in the remodelling of skeletal muscle, 10.1079/par2004358
  5. Bodine S. C., Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy, 10.1126/science.1065874
  6. Baptista Igor L., Leal Marcelo L., Artioli Guilherme G., Aoki Marcelo S., Fiamoncini Jarlei, Turri Antonio O., Curi Rui, Miyabara Elen H., Moriscot Anselmo S., Leucine attenuates skeletal muscle wasting via inhibition of ubiquitin ligases, 10.1002/mus.21578
  7. Dupont-Versteegden E. E., Effect of flywheel-based resistance exercise on processes contributing to muscle atrophy during unloading in adult rats, 10.1152/japplphysiol.01540.2005
  8. Kisselev Alexei F., Goldberg Alfred L., Proteasome inhibitors: from research tools to drug candidates, 10.1016/s1074-5521(01)00056-4
  9. Combaret L., USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states, 10.1152/ajpendo.00281.2004
  10. Tawa N E, Odessey R, Goldberg A L, Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles., 10.1172/jci119513
  11. Kadlčíková Jana, Holeček Milan, Šafránek Roman, Tilšer Ivan, Kessler Benedikt M., Effects of proteasome inhibitors MG132, ZL3VS and AdaAhx3L3VS on protein metabolism in septic rats : Proteasome inhibitors in sepsis, 10.1111/j.0959-9673.2004.00405.x
  12. Bonuccelli Gloria, Sotgia Federica, Schubert William, Park David S., Frank Philippe G., Woodman Scott E., Insabato Luigi, Cammer Michael, Minetti Carlo, Lisanti Michael P., Proteasome Inhibitor (MG-132) Treatment of mdx Mice Rescues the Expression and Membrane Localization of Dystrophin and Dystrophin-Associated Proteins, 10.1016/s0002-9440(10)63523-7
  13. Šafránek Roman, Ishibashi Nobuya, Oka Youske, Ozasa Hiroyuki, Shirouzu Kazuo, Holeček Milan, Modulation of inflammatory response in sepsis by proteasome inhibition : Proteasome and inflammatory response, 10.1111/j.1365-2613.2006.00490.x
  14. Supinski G. S., Vanags J., Callahan L. A., Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction, 10.1152/ajplung.90404.2008
  15. Krawiec, Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis, 289, E969 (2005)
  16. Beehler, Exp Biol Med (Maywood), 231, 335 (2006)
  17. Deldicque L., Theisen D., Bertrand L., Hespel P., Hue L., Francaux M., Creatine enhances differentiation of myogenic C2C12 cells by activating both p38 and Akt/PKB pathways, 10.1152/ajpcell.00162.2007
  18. Chopard Angèle, Hillock Steven, Jasmin Bernard J., Molecular events and signalling pathways involved in skeletal muscle disuse-induced atrophy and the impact of countermeasures, 10.1111/j.1582-4934.2009.00864.x
  19. Ferreira Rita, Vitorino Rui, Neuparth Maria João, Appell Hans-Joachim, Duarte José Alberto, Amado Francisco, Proteolysis activation and proteome alterations in murine skeletal muscle submitted to 1 week of hindlimb suspension, 10.1007/s00421-009-1151-1
  20. Orlowski Robert Z., Stinchcombe Thomas E., Mitchell Beverly S., Shea Thomas C., Baldwin Albert S., Stahl Stephanie, Adams Julian, Esseltine Dixie-Lee, Elliott Peter J., Pien Christine S., Guerciolini Roberto, Anderson Jessica K., Depcik-Smith Natalie D., Bhagat Rita, Lehman Mary Jo, Novick Steven C., O’Connor Owen A., Soignet Steven L., Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies, 10.1200/jco.2002.01.133
  21. Holecek Milan, Muthny Tomas, Kovarik Miroslav, Sispera Ludek, Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat, 10.1016/j.bbrc.2006.04.053
  22. Koncarevic A., Jackman R. W., Kandarian S. C., The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension, 10.1096/fj.06-6665com
  23. Wing Simon S., Control of ubiquitination in skeletal muscle wasting, 10.1016/j.biocel.2004.11.011
  24. Zhang Peng, Chen Xiaoping, Fan Ming, Signaling mechanisms involved in disuse muscle atrophy, 10.1016/j.mehy.2006.11.043
  25. Berthon P., Duguez S., Favier F. B., Amirouche A., Feasson L., Vico L., Denis C., Freyssenet D., Regulation of ubiquitin–proteasome system, caspase enzyme activities, and extracellular proteinases in rat soleus muscle in response to unloading, 10.1007/s00424-007-0230-6
  26. Farout Luc, Lamare Marie Christine, Cardozo Christopher, Harrisson Michael, Briand Yves, Briand Marièle, Distribution of Proteasomes and of the Five Proteolytic Activities in Rat Tissues, 10.1006/abbi.1999.1585
  27. Glickman Michael H., Ciechanover Aaron, The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction, 10.1152/physrev.00027.2001
  28. Lee Do Hee, Goldberg Alfred L, Proteasome inhibitors: valuable new tools for cell biologists, 10.1016/s0962-8924(98)01346-4
  29. Ferrington, FASEB J, 19, 644 (2005)
  30. Stohwasser Ralf, Salzmann Ulrike, Giesebrecht Jan, Kloetzel Peter-Michael, Holzhütter Hermann-Georg, Kinetic evidences for facilitation of peptide channelling by the proteasome activator PA28 : recPA28 mediated proteasome activation, 10.1046/j.1432-1327.2000.01706.x
  31. Rechsteiner Martin, Hill Christopher P., Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors, 10.1016/j.tcb.2004.11.003
  32. Attaix Didier, Taillandier Daniel, Combaret Lydie, Rallière Cécile, Larbaud Daniel, Aurousseau Eveline, Tanaka Keiji, 10.1023/a:1006806103675
  33. Ustrell Vicença, Pratt Gregory, Gorbea Carlos, Rechsteiner Martin, Purification and Assay of Proteasome Activator PA200, Methods in Enzymology (2005) ISBN:9780121828035 p.321-329, 10.1016/s0076-6879(05)98026-9
  34. Zong C., Regulation of Murine Cardiac 20S Proteasomes: Role of Associating Partners, 10.1161/01.res.0000237389.40000.02
  35. Myung Jayhyuk, Kim Kyung Bo, Crews Craig M., The ubiquitin-proteasome pathway and proteasome inhibitors, 10.1002/med.1009
  36. Kupperman E., Lee E. C., Cao Y., Bannerman B., Fitzgerald M., Berger A., Yu J., Yang Y., Hales P., Bruzzese F., Liu J., Blank J., Garcia K., Tsu C., Dick L., Fleming P., Yu L., Manfredi M., Rolfe M., Bolen J., Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer, 10.1158/0008-5472.can-09-2766
  37. Attar E. C., DeAngelo D. J., Supko J. G., D'Amato F., Zahrieh D., Sirulnik A., Wadleigh M., Ballen K. K., McAfee S., Miller K. B., Levine J., Galinsky I., Trehu E. G., Schenkein D., Neuberg D., Stone R. M., Amrein P. C., Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia, 10.1158/1078-0432.ccr-07-4626
  38. Lightcap, Clin Chem, 46, 673 (2000)